Skip to main content

Women's Journal

Why Osteoarthritis Finds Women More Often After 50 and A September Review Traces the Hormone Link and the Gaps

By: Alena Wiese

A peer-reviewed review published Sept. 11, 2026, pulls together evidence linking menstruation, pregnancy, breastfeeding and menopause to a woman’s risk of osteoarthritis. It also points out how little is known about whether those factors should change treatment, which is why first-line, non-surgical care still matters.

A woman in her early 50s may first notice it in small ways. Her fingers feel stiff when she twists the lid off a jar. Her knees protest after a long drive home on Interstate 4. She may wonder whether the aches are just part of getting older, part of menopause, or something she can do something about.

The honest answer is that it can be all three. Women are more likely than men to have osteoarthritis, and researchers increasingly link that gap to sex hormones across a woman’s lifetime, including the menopause transition. But the same research makes clear that the main tools for managing osteoarthritis, including exercise, weight management and education, remain the first steps for women and men alike.

On Sept. 11, 2026, the International Journal of Molecular Sciences published a review by researchers from the Robert Jones and Agnes Hunt Orthopaedic Hospital, Keele University and the University of Liverpool in the United Kingdom. It examined osteoarthritis risk from a woman’s first period through menopause and concluded that a strong body of evidence links sex-hormone-regulated processes across the female life course with increased osteoarthritis risk.

Are Women Really More Likely to Get Osteoarthritis Than Men?

Yes. A Centers for Disease Control and Prevention analysis of national survey data found that the age-standardized prevalence of diagnosed arthritis was 20.9 percent among women compared with 16.3 percent among men. Overall, 53.2 million U.S. adults reported diagnosed arthritis, and nearly half of them were 65 or older.

The National Institutes of Health puts the pattern plainly on its osteoarthritis page: women are more likely than men to have osteoarthritis, especially after age 50.

Source: Prevalence of Diagnosed Arthritis, United States, 2019 to 2021, Morbidity and Mortality Weekly Report, Centers for Disease Control and Prevention, October 2023.

What Did the New Review Find About Menopause and Women’s Joints?

The review found that milestones across a woman’s life, from menarche to pregnancy, breastfeeding, and menopause, are tied to osteoarthritis risk through hormones, biomechanics, immune and metabolic function, and pain pathways. The authors searched medical databases through July 2026.

Among the findings, the review highlights from earlier studies:

  • After age 50, women consistently have higher osteoarthritis incidence, more severe disease, and higher rates of joint replacement than men.
  • More than 70 percent of women experience musculoskeletal symptoms during the menopause transition, and 25 percent are disabled by them.
  • In one cohort, women reporting five or more births had a 2.6-fold higher adjusted risk of new radiographic knee osteoarthritis, and a 2.7-fold increase in knee replacements over 30 months compared with women reporting one birth.
  • Females have roughly a 2 to 6 times higher incidence of anterior cruciate ligament injury than males, and about 20 percent of people develop moderate to severe radiographic osteoarthritis within 10 years of an ACL injury.

The review also states that women show poorer responses than men to both surgical and non-surgical musculoskeletal treatment.

Source: A Thematic Narrative Review of Osteoarthritis Risk Factors Across the Female Life Course, International Journal of Molecular Sciences, September 2026.

What Can This Review Not Prove?

It does not tell a woman that menopause caused her arthritis, or that any hormone treatment will prevent it. This is a narrative review, which gathers and interprets existing research rather than pooling data into new statistical estimates, and the figures it cites come from earlier studies with their own designs and limits.

Most of the associations described are just that: associations, not proof of cause. The authors note that much of the available mechanistic evidence concerns the knee, with comparatively less for the hip and hand, even though hand osteoarthritis is common in midlife women. Most important for patients, the review says little research has examined whether sex, menopausal status or hormonal factors change how well treatments work. That gap is a reason for curiosity in the exam room, not a reason to skip proven basics.

What Non-Surgical Options Should Women Ask About First?

Women should ask first about exercise, weight management and physical therapy, which the National Institutes of Health lists among core osteoarthritis treatments. The National Institute of Arthritis and Musculoskeletal and Skin Diseases notes that exercise can lower joint pain and stiffness and increase flexibility and muscle strength.

Other options the institute describes include braces or orthotics prescribed by a doctor, assistive devices such as canes and grip aids, and heat and cold therapies. Medications and surgery are reserved for select cases.

Source: Osteoarthritis, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, accessed September 2026.

How Does an Orlando Practice Evaluate Joint Pain in Women?

A careful evaluation starts with history: which joints hurt, when symptoms began, how they respond to activity, and where a woman is in the menopause transition. ReliefNow Laser Orlando, at 4170 Town Center Blvd., Suite 100, Orlando (407-857-6166), serves Orlando and Kissimmee across south Orange County and Osceola County. Its chiropractors are Dr. Jeff Shebovsky, Dr. Fernando Fernandez, and Dr. Kurt Virgin.

Dr. Jeffrey N. Shebovsky, DC, founded Orange Wellness in 1994 and holds a Doctor of Chiropractic degree from New York Chiropractic College, where he graduated with honors. The practice lists arthritis and joint pain among the conditions it evaluates.

The need is large locally. The U.S. Census Bureau estimates Orange County’s population at 1,528,002 as of July 2025, with women making up 51.4 percent of residents and 14.3 percent of residents 65 or older.

Conservative care is a reasonable starting point for many women with mild to moderate osteoarthritis. Some symptoms need a physician promptly: a hot, swollen joint with fever; several swollen joints with morning stiffness that lasts a long time, which can signal rheumatoid arthritis or another inflammatory condition that is also more common in women; unexplained weight loss; or pain after a fall that could mean a fracture, a real concern after menopause. Calf swelling and pain in one leg need emergency care.

When progress is tracked, it should be in terms a woman recognizes from her own week: how long she can walk, whether stairs feel easier, whether she can open that jar, and how pain scores change over time. When advanced damage and declining function persist despite consistent care, a referral to an orthopedic specialist is the appropriate next step.

For many women, midlife is when the body starts asking new questions. The research is finally starting to ask them too, and until it has fuller answers, steady movement, good information, and a thorough evaluation remain a practical place to begin.

ABOUT: Dr. Jeffrey N. Shebovsky, DC | ReliefNow® Laser Orlando | 4170 Town Center Blvd., Suite 100, Orlando, FL 32837 | 407-857-6166

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before beginning any treatment program.

Why Osteoarthritis Finds Women More Often After 50: A September Review Traces the Hormone Link, and the Gaps

A peer-reviewed review published Sept. 11, 2026, pulls together evidence linking menstruation, pregnancy, breastfeeding and menopause to a woman’s risk of osteoarthritis. It also points out how little is known about whether those factors should change treatment, which is why first-line, non-surgical care still matters.

By Alena Wiese

A woman in her early 50s may first notice it in small ways. Her fingers feel stiff when she twists the lid off a jar. Her knees protest after a long drive home on Interstate 4. She may wonder whether the aches are just part of getting older, part of menopause, or something she can do something about.

The honest answer is that it can be all three. Women are more likely than men to have osteoarthritis, and researchers increasingly link that gap to sex hormones across a woman’s lifetime, including the menopause transition. But the same research makes clear that the main tools for managing osteoarthritis, including exercise, weight management and education, remain the first steps for women and men alike.

On Sept. 11, 2026, the International Journal of Molecular Sciences published a review by researchers from the Robert Jones and Agnes Hunt Orthopaedic Hospital, Keele University and the University of Liverpool in the United Kingdom. It examined osteoarthritis risk from a woman’s first period through menopause and concluded that a strong body of evidence links sex-hormone-regulated processes across the female life course with increased osteoarthritis risk.

Are women really more likely to get osteoarthritis than men?

Yes. A Centers for Disease Control and Prevention analysis of national survey data found that the age-standardized prevalence of diagnosed arthritis was 20.9 percent among women compared with 16.3 percent among men. Overall, 53.2 million U.S. adults reported diagnosed arthritis, and nearly half of them were 65 or older.

The National Institutes of Health puts the pattern plainly on its osteoarthritis page: women are more likely than men to have osteoarthritis, especially after age 50.

Source: Prevalence of Diagnosed Arthritis, United States, 2019 to 2021, Morbidity and Mortality Weekly Report, Centers for Disease Control and Prevention, October 2023. https://www.cdc.gov/mmwr/volumes/72/wr/mm7241a1.htm

What did the new review find about menopause and women’s joints?

The review found that milestones across a woman’s life, from menarche to pregnancy, breastfeeding and menopause, are tied to osteoarthritis risk through hormones, biomechanics, immune and metabolic function, and pain pathways. The authors searched medical databases through July 2026.

Among the findings the review highlights from earlier studies:

  • After age 50, women consistently have higher osteoarthritis incidence, more severe disease and higher rates of joint replacement than men.
  • More than 70 percent of women experience musculoskeletal symptoms during the menopause transition, and 25 percent are disabled by them.
  • In one cohort, women reporting five or more births had a 2.6-fold higher adjusted risk of new radiographic knee osteoarthritis, and a 2.7-fold increase in knee replacements over 30 months compared with women reporting one birth.
  • Females have roughly a 2 to 6 times higher incidence of anterior cruciate ligament injury than males, and about 20 percent of people develop moderate to severe radiographic osteoarthritis within 10 years of an ACL injury.

The review also states that women show poorer responses than men to both surgical and non-surgical musculoskeletal treatment.

Source: A Thematic Narrative Review of Osteoarthritis Risk Factors Across the Female Life Course, International Journal of Molecular Sciences, September 2026. https://www.mdpi.com/1422-0067/27/18/8083

What can this review not prove?

It does not tell a woman that menopause caused her arthritis, or that any hormone treatment will prevent it. This is a narrative review, which gathers and interprets existing research rather than pooling data into new statistical estimates, and the figures it cites come from earlier studies with their own designs and limits.

Most of the associations described are just that: associations, not proof of cause. The authors note that much of the available mechanistic evidence concerns the knee, with comparatively less for the hip and hand, even though hand osteoarthritis is common in midlife women. Most important for patients, the review says little research has examined whether sex, menopausal status or hormonal factors change how well treatments work. That gap is a reason for curiosity in the exam room, not a reason to skip proven basics.

What non-surgical options should women ask about first?

Women should ask first about exercise, weight management and physical therapy, which the National Institutes of Health lists among core osteoarthritis treatments. The National Institute of Arthritis and Musculoskeletal and Skin Diseases notes that exercise can lower joint pain and stiffness and increase flexibility and muscle strength.

Other options the institute describes include braces or orthotics prescribed by a doctor, assistive devices such as canes and grip aids, and heat and cold therapies. Medications and surgery are reserved for select cases.

Source: Osteoarthritis, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, accessed September 2026. https://www.niams.nih.gov/health-topics/osteoarthritis

How does an Orlando practice evaluate joint pain in women?

A careful evaluation starts with history: which joints hurt, when symptoms began, how they respond to activity, and where a woman is in the menopause transition. ReliefNow Laser Orlando, at 4170 Town Center Blvd., Suite 100, Orlando (407-857-6166), serves Orlando and Kissimmee across south Orange County and Osceola County. Its chiropractors are Dr. Jeff Shebovsky, Dr. Fernando Fernandez and Dr. Kurt Virgin.

Dr. Jeffrey N. Shebovsky, DC, founded Orange Wellness in 1994 and holds a Doctor of Chiropractic degree from New York Chiropractic College, where he graduated with honors. The practice lists arthritis and joint pain among the conditions it evaluates.

The need is large locally. The U.S. Census Bureau estimates Orange County’s population at 1,528,002 as of July 2025, with women making up 51.4 percent of residents and 14.3 percent of residents 65 or older.

Conservative care is a reasonable starting point for many women with mild to moderate osteoarthritis. Some symptoms need a physician promptly: a hot, swollen joint with fever; several swollen joints with morning stiffness that lasts a long time, which can signal rheumatoid arthritis or another inflammatory condition that is also more common in women; unexplained weight loss; or pain after a fall that could mean a fracture, a real concern after menopause. Calf swelling and pain in one leg needs emergency care.

When progress is tracked, it should be in terms a woman recognizes from her own week: how long she can walk, whether stairs feel easier, whether she can open that jar, and how pain scores change over time. When advanced damage and declining function persist despite consistent care, a referral to an orthopedic specialist is the appropriate next step.

For many women, midlife is when the body starts asking new questions. The research is finally starting to ask them too, and until it has fuller answers, steady movement, good information and a thorough evaluation remain a practical place to begin.

ABOUT: Dr. Jeffrey N. Shebovsky, DC | ReliefNow® Laser Orlando | 4170 Town Center Blvd., Suite 100, Orlando, FL 32837 | 407-857-6166 | https://reliefnowlaser.com/providers/orlando/

This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before beginning any treatment program.

A Grandmother’s Legacy Inspires Flora Marteen’s Romantic Resort Collection for 2027

Jennifer Peykar celebrates femininity, family and the confidence of women through Flora Marteen’s Buenos Aires Resort Collection 2027.

Some women leave behind photographs. Some leave recipes, traditions or treasured pieces of jewelry.

Others leave behind a philosophy that quietly influences generations.

For designer Jennifer Peykar, her grandmother left her an understanding of elegance that would ultimately become the foundation for Flora Marteen, the luxury resort wear label named in her honor.

That relationship takes center stage in Peykar’s newest chapter: the Buenos Aires Resort Collection 2027.

“My grandmother taught me that beautiful clothing isn’t about excess,” Peykar says. “It’s about confidence, quality, and creating something that makes a woman feel extraordinary.”

It is a sentiment that captures the spirit of the collection.

Dressing the Woman, Not Overpowering Her

At Flora Marteen, the woman is intended to remain the focal point.

Rather than relying on excess, the Buenos Aires collection embraces flowing silhouettes, refined lace, lightweight knits, seamless designs and subtle metallic elements.

Peykar found her muse in Buenos Aires, a city famous for its striking architecture, romantic streets, European influence and Latin American spirit.

Imagine an afternoon wandering through Recoleta, stopping at a café along a cobblestone street and later changing the mood, not necessarily the entire outfit, for an evening of cocktails, dinner and music.

That effortless transformation is central to Peykar’s vision.

The collection’s movement also pays homage to tango. Fluid silhouettes create a sense of freedom and femininity, while metallic fabrics recall the glow of Buenos Aires after dark.

Clothes That Travel With Women

Modern women rarely live their lives in a single setting, and Peykar designs accordingly.

Resort wear today is no longer confined to the beach.

A woman might wear the same dress while enjoying lunch on the Amalfi Coast, attending a summer event in the Hamptons, boarding a yacht in the Mediterranean or dining in St. Barths.

Flora Marteen creates pieces intended to travel through those moments with her.

A lightweight knit dress worn with sandals during the day can take on an entirely different personality with heels and jewelry at night. Relaxed silhouettes provide comfort without sacrificing polish, while delicate details bring femininity without making the clothing feel overdone.

A Legacy Passed From One Woman to Another

Perhaps the most meaningful element of the Buenos Aires Resort Collection 2027 is that its inspiration reaches beyond fashion.

It is a story about what women teach other women.

Peykar’s grandmother influenced how she understood quality, confidence and beauty. Today, those lessons have become part of a brand designed for another generation of women.

The result feels particularly relevant in a fashion culture often dominated by what is newest, fastest or most visible.

Flora Marteen offers another idea: that style can be quiet and still command attention.

For Peykar, timelessness is not about looking backward. It is about taking something meaningful from the past and allowing it to evolve.

Through the Buenos Aires Resort Collection 2027, a grandmother’s influence lives on, not only in her name, but in every woman who puts on Flora Marteen and feels extraordinary.

https://floramarteen.com/

New SCAD Trial Advances Research Into Women’s Heart Health

Mount Sinai has received a $2 million grant from the National Heart, Lung, and Blood Institute to begin the U.S. feasibility phase of an international SCAD clinical trial. The study will compare treatment strategies for spontaneous coronary artery dissection, a heart condition that occurs predominantly in women.

The research addresses a significant evidence gap in SCAD care, where treatment approaches have largely been adapted from other forms of heart attack despite important differences in how the condition develops.

Key Takeaways

  • Mount Sinai received a $2 million grant from the National Heart, Lung, and Blood Institute
  • The funding supports a one-year U.S. feasibility phase of an international clinical trial
  • Researchers will compare two antiplatelet treatment strategies for spontaneous coronary artery dissection
  • About 80% to 95% of SCAD cases occur in women, Mount Sinai reports
  • The international trial plans to enroll about 3,500 patients, including approximately 500 participants in the United States

Mount Sinai Receives $2 Million for SCAD Trial

The $2 million grant will support the U.S. feasibility phase of an international study examining treatment for spontaneous coronary artery dissection, commonly known as SCAD. Mount Sinai is leading the U.S. portion of the research.

SCAD occurs when a spontaneous tear or separation develops within the wall of a coronary artery. Blood can accumulate within the artery wall, narrowing or blocking blood flow and potentially causing a heart attack.

Unlike many heart attacks associated with atherosclerotic plaque buildup, SCAD begins within the artery wall. It can affect people who have few or none of the cardiovascular risk factors commonly associated with coronary artery disease.

Mount Sinai reports that roughly 80% to 95% of SCAD cases occur in women, with many affected women between ages 42 and 52. That age range overlaps with a period when other research has documented cardiovascular changes during perimenopause, although SCAD is a distinct condition and the new trial is focused specifically on its treatment.

The National Heart, Lung, and Blood Institute, part of the National Institutes of Health, is funding the one-year feasibility phase. The initial work is intended to establish the foundation for a larger U.S. component of the international trial.

Clinical Trial Compares SCAD Treatment Strategies

The study will compare two antiplatelet approaches in patients with SCAD. One strategy uses aspirin alone, while the other involves more intensive antiplatelet therapy.

Antiplatelet medicines reduce the ability of platelets in the blood to stick together and form clots. They are commonly used after conventional heart attacks, but researchers do not yet have large-scale randomized evidence establishing the optimal antiplatelet strategy specifically for SCAD.

That distinction matters because SCAD differs from the cholesterol-related blockages responsible for many other heart attacks. The underlying problem involves the coronary artery wall rather than the same type of atherosclerotic plaque disruption seen in typical coronary artery disease.

As a result, treatment practices developed for more common forms of heart attack may not necessarily produce the same balance of benefits and risks in people with SCAD.

The international trial is designed to generate direct evidence by comparing patient outcomes under the two treatment strategies. Researchers will assess cardiovascular outcomes including heart attack, recurrent SCAD, stroke, bleeding and other major events.

The study does not assume that either approach is superior. Its purpose is to provide randomized evidence that can better inform future treatment decisions.

SCAD Disproportionately Affects Women

Women make up the large majority of patients diagnosed with SCAD. Mount Sinai estimates that approximately 80% to 95% of cases occur in women.

Many affected patients also differ from the population commonly associated with coronary artery disease. Women with SCAD may have few traditional cardiovascular risk factors such as high cholesterol or diabetes.

SCAD can narrow or block a coronary artery and cause a heart attack, making timely medical evaluation important when symptoms occur. Broader research into heart attack symptoms in women has highlighted the importance of recognizing cardiovascular events across female patient populations.

The new trial focuses specifically on what happens after SCAD is diagnosed. Researchers are examining how different antiplatelet strategies affect outcomes rather than testing a lifestyle-based prevention program.

The concentration of SCAD cases among women also makes the trial relevant to a broader effort to improve evidence for cardiovascular conditions that disproportionately affect female patients.

International Trial Plans to Enroll About 3,500 Patients

Researchers plan to enroll approximately 3,500 patients across the international clinical trial, including about 500 participants in the United States.

The U.S. component is expected to involve roughly 60 clinical sites. The larger international collaboration includes investigators and funding organizations across multiple countries, allowing researchers to study a condition that individual centers may encounter relatively infrequently.

That scale is particularly important for SCAD because its lower prevalence makes it difficult for a single hospital or research network to enroll enough patients for a large randomized trial.

The study will use a common research protocol across participating locations, allowing investigators to compare treatment outcomes across a much larger patient population.

Planned enrollment figures describe the intended scale of the broader study rather than the number of patients who have already entered the trial. The current NIH award supports the initial U.S. feasibility work that precedes the larger domestic study.

By combining research networks across countries, investigators aim to build a body of evidence large enough to address questions that smaller observational studies have been unable to resolve.

U.S. Feasibility Phase Sets Up Larger Study

The one-year U.S. feasibility phase is the first step toward a larger domestic component of the international clinical trial.

Mount Sinai will use the initial NIH funding to establish the U.S. research infrastructure and evaluate the feasibility of expanding enrollment across participating sites. A larger U.S. study would require additional funding.

The research centers on a practical clinical question: whether aspirin alone or a more intensive antiplatelet approach provides the appropriate treatment strategy for patients with SCAD.

Current practice has developed without a large randomized trial specifically testing these approaches in the SCAD population. The international study is designed to help close that evidence gap.

Researchers plan to evaluate a range of cardiovascular outcomes, including recurrent SCAD and bleeding, to understand the effects of each strategy rather than focusing on a single measure.

For a condition that disproportionately affects women and can occur without conventional coronary risk factors, the study represents a substantial effort to generate treatment evidence directly from patients with SCAD.

Frequently Asked Questions

What is spontaneous coronary artery dissection?

Spontaneous coronary artery dissection, or SCAD, occurs when a spontaneous tear or separation develops within the wall of a coronary artery. This can narrow or block blood flow and cause a heart attack.

What is the new SCAD clinical trial studying?

The trial will compare aspirin alone with a more intensive antiplatelet treatment strategy in patients diagnosed with SCAD. Researchers will evaluate cardiovascular and bleeding outcomes associated with the two approaches.

Why is SCAD closely associated with women’s heart health?

Mount Sinai reports that approximately 80% to 95% of SCAD cases occur in women, many of whom are between ages 42 and 52 and may have few traditional cardiovascular risk factors.

How many patients will participate in the SCAD trial?

Researchers plan to enroll approximately 3,500 patients internationally. About 500 participants are expected to join the U.S. portion of the trial across roughly 60 sites.

Who is funding the SCAD clinical trial?

The National Heart, Lung, and Blood Institute, part of the National Institutes of Health, awarded Mount Sinai $2 million to support the one-year U.S. feasibility phase.

Disclaimer:

This article is for informational purposes only and does not constitute medical advice, diagnosis or treatment. Anyone experiencing symptoms of a heart attack or other medical emergency should seek immediate medical care. Questions about SCAD, medications or treatment options should be discussed with a qualified healthcare professional.